 
|
|
Immune to the downturn?
One glance into the national papers confirms that the public is engaged in an intense discussion around vaccines. The discussion rages on around swine flu, Bird flu, SARS and other potential pandemics, which has moved the vaccine market into the focus of not only public interest but has also re-invigorated the pharmaceutical companies to develop new vaccine products.
The history of vaccines started around 200 years ago, when Dr. Edward Jenner carried out the first smallpox vaccination, unaware at that time what a revolution this would turn out to be in preventative medicine and healthcare. The last century saw frantic research emerge for new vaccines, mostly centered around infectious diseases until the eighties and nineties when the love affair and business with vaccines seemed to slow. Some pharmaceutical companies even withdrew from the segment, as profit margins became squeezed and major breakthroughs failed to materialize due to a lack of further research and development investments. However, the former ‘stepchild’ of the pharmaceutical industry has undergone a literal renaissance in the recent years, due to governments’ preventive campaigns to counteract potential pandemics and the modern day dependence on international travel. New developments in genomic research have opened up the path to the development of alternative products. Innovative vaccines promise potential multi-billion dollar sales and public funding by health authorities to subsidize research and development has ushered in a new era for vaccines.
[...]
Only excellent product knowledge allows perfect adaptation of machines to customer requirements and Optima Group Pharma proudly claims a leadership role in this area. It is our goal to enable customers to benefit from the process knowledge and outstanding performance of our machines – in particular within the vaccine segment.
Interested in the whole article? No problem. Just send an e-mail with the password „Vaccines“ to info@optima-pharma.com
|
back
